Areva Med acquires Macrocyclics

10/20/2011 | MolecularImaging.net

Areva Med, a subsidiary of Areva that develops the radioisotope lead-212, has acquired Macrocyclics. Macrocyclics produces chemical agents used to bind antibodies or proteins to radioisotopes for some nuclear medicine cancer treatments. Areva is building the Maurice Tubiana Laboratory in France for the production of medical-grade lead-212.

View Full Article in:

MolecularImaging.net

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ